CPH.TO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 09:34):

Stats
Today's Volume	6 116.00
Average Volume	46 258.00
Market Cap	206.59M
EPS	$0.400 ( 2024-03-15 )
Next earnings date	( $0.190 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	7.82
ATR14	$0.0390 (0.45%)

Cipher Pharmaceuticals Correlation

10 Most Positive Correlations
ATD.TO	0.901
RQL.TO	0.886
CCO.TO	0.87
BDT.TO	0.865
PKI.TO	0.863
BDI.TO	0.863
RQN.TO	0.857
CMG.TO	0.857
SNC.TO	0.837
THNC.TO	0.832

10 Most Negative Correlations
HOT-UN.TO	-0.899
GEO.TO	-0.858
LGO.TO	-0.857
WEF.TO	-0.852
PLRB.V	-0.852
HEXO.TO	-0.838
BYL.TO	-0.835
CRRX.TO	-0.831
FIL.TO	-0.831
S.TO	-0.827

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cipher Pharmaceuticals Financials

Annual	2023
Revenue:	$21.16M
Gross Profit:	$17.09M (80.77 %)
EPS:	$0.820

Q4	2023
Revenue:	$4.92M
Gross Profit:	$3.97M (80.59 %)
EPS:	$0

Q3	2023
Revenue:	$6.07M
Gross Profit:	$4.99M (82.27 %)
EPS:	$0.280

Q2	2023
Revenue:	$5.29M
Gross Profit:	$4.23M (79.94 %)
EPS:	$0.120

Financial Reports:

No articles found.

Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.